Citius Oncology (CTOR) Liabilities and Shareholders Equity (2021 - 2026)

Citius Oncology's Liabilities and Shareholders Equity history runs 6 years deep, the most recent figure standing at $100.7 million for Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity rose 10.13% year-over-year to $100.7 million; the TTM figure through Mar 2026 stood at $403.3 million (up 27.84% YoY), while the FY2025 annual figure was $100.9 million, up 19.64% from the prior year.
• Liabilities and Shareholders Equity was $100.7 million for Q1 2026 at Citius Oncology, down from $110.0 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $110.0 million in Q4 2025 to a low of $256745.0 in Q3 2022.
• Historically, Liabilities and Shareholders Equity has averaged $73.0 million across 5 years, with a median of $72.6 million in 2023.
• The sharpest annual moves came in 2022 and 2024: Liabilities and Shareholders Equity soared 53838.68% in 2022, then decreased 29.57% in 2024.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $68.2 million in 2022, then gained by 6.5% to $72.6 million in 2023, then climbed by 24.59% to $90.5 million in 2024, then advanced by 21.54% to $110.0 million in 2025, then declined by 8.43% to $100.7 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $100.7 million (Q1 2026), $110.0 million (Q4 2025), and $100.9 million (Q3 2025), per Business Quant data.